KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Charles River Laboratories International (CRL) Equity Income (2016)

Charles River Laboratories International has reported Equity Income over the past 5 years, most recently at $442000.0 for Q3 2016.

  • For Q3 2016, Equity Income fell 86.36% year-over-year to $442000.0; the TTM value through Sep 2016 reached $8.7 million, up 58.08%, while the annual FY2015 figure was $3.8 million, 58.89% down from the prior year.
  • Equity Income for Q3 2016 was $442000.0 at Charles River Laboratories International, down from $5.0 million in the prior quarter.
  • Over five years, Equity Income peaked at $6.1 million in Q1 2014 and troughed at -$907000.0 in Q2 2015.
  • A 5-year average of $1.4 million and a median of $1.1 million in 2013 define the central range for Equity Income.
  • Biggest five-year swings in Equity Income: surged 6882.22% in 2014 and later plummeted 143.69% in 2015.
  • Year by year, Equity Income stood at -$373000.0 in 2012, then skyrocketed by 386.33% to $1.1 million in 2013, then skyrocketed by 80.06% to $1.9 million in 2014, then crashed by 88.61% to $219000.0 in 2015, then skyrocketed by 101.83% to $442000.0 in 2016.
  • Business Quant data shows Equity Income for CRL at $442000.0 in Q3 2016, $5.0 million in Q2 2016, and $3.1 million in Q1 2016.